David R. Oveisi, MD, discusses the importance of clear communication with patients prior to administering CAR T-cell therapy for multiple myeloma.
David R. Oveisi, MD
Advertisement
Articles by David R. Oveisi, MD
David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.
Advertisement
Latest Updated Articles
Dr Oveisi on the Potential Role of Bispecific Antibodies in Multiple MyelomaPublished: June 30th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5